Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 4

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT01742117Phase 4Completed

Tailored Antiplatelet Therapy Following PCI

Role: collaborator

NCT04575168Completed

Clinical Study Spartan COVID-19 V2 System

Role: lead

NCT04628208Completed

Clinical Study Spartan COVID-19 V2 System (Canada Alternate)

Role: lead

NCT04473248Not ApplicableCompleted

Spartan COVID-19 System: Evaluation of Clinical Sample Collection

Role: lead

NCT04473586Not ApplicableCompleted

Spartan Cube CYP2C19 Method Comparison Study

Role: lead

NCT04473573Not ApplicableCompleted

Spartan Cube CYP2C19 Inter Laboratory Reproducibilty Study

Role: lead

NCT01718535Completed

Method Comparison Study of the Spartan FRX CYP2C19 Genotyping System Against Bi-directional Sequencing

Role: lead

NCT01452139Phase 2Completed

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

Role: collaborator

NCT01676298Completed

Spartan FRX Project Reproducibility Study

Role: lead

NCT01184300Phase 2Completed

ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation

Role: collaborator

All 10 trials loaded